Inotiv

27 articles about Inotiv

• Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update

  2/7/2024

  Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q1 FY 2024”) ended December 31, 2023.

• Inotiv, Inc. to Report Fiscal 2024 First Quarter Financial Results and Host Conference Call on Wednesday, February 7, 2024

  1/29/2024

  Inotiv, Inc. announced that it will issue its financial results for the fiscal 2024 first quarter ended December 31, 2023, on Wednesday, February 7, 2024, after the close of the stock market.

• Inotiv, Inc. to Report Fiscal 2023 Fourth Quarter and Full Year Results and Host Conference Call on Monday, December 11, 2023

  11/27/2023

  Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”) today announced that it will issue its financial results for the fiscal 2023 fourth quarter and full year ended September 30, 2023, on Monday, December 11, 2023, after the close of the stock market.

• Inotiv Provides Business Updates and Upcoming Investor Conferences Update - November 13, 2023

  11/13/2023

  Inotiv, Inc., a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, provides business updates related to Inotiv’s operations and an update regarding its participation in upcoming investor conferences.

• Inotiv, Inc. to Participate in Upcoming November 2023 Investor Conferences

  11/1/2023

  Inotiv, Inc. announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in multiple upcoming investor conferences throughout November 2023.

• Inotiv, Inc. Announces Changes to its Board Composition

  10/16/2023

  Inotiv, Inc., a leading contract research organization, announced the appointment of Terry Coelho to its Board of Directors.

• Inotiv Announces the Sale of its Israeli Businesses to Harlan Holdings Ltd.

  8/29/2023

  Inotiv, Inc., a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced the completion of the sale of its businesses in Israel.

• Inotiv Reports Third Quarter Financial Results for Fiscal 2023 and Provides Business Update

  8/10/2023

  Inotiv, Inc., a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced financial results for the three months and nine months ended June 30, 2023.

• Inotiv, Inc. to Report Fiscal 2023 Third Quarter Financial Results and Host Conference Call on Thursday, August 10, 2023

  7/24/2023

  Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 third quarter ended June 30, 2023, on Thursday, August 10, 2023, after the close of the stock market.

• Inotiv, Inc. to Present at Jefferies 2023 Healthcare Conference

  5/25/2023

  Inotiv, Inc. announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will present at the Jefferies Healthcare Conference, being held in New York, NY, from June 7-9, 2023.

• Inotiv, Inc. Announces Second Quarter Fiscal 2023 Financial Results

  5/11/2023

  Inotiv, Inc., a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced financial results for the three months and six months ended March 31, 2023.

• Inotiv, Inc. Expands Safety Pharmacology Offering to Include Cardiopulmonary Telemetry

  5/4/2023

  Inotiv, Inc. announced the expansion of the Company’s safety pharmacology offering with the validation and verification of a cardiopulmonary telemetry study model in cynomolgus macaques.

• Inotiv, Inc. to Report Fiscal 2023 Second Quarter Financial Results and Host Conference Call on Thursday, May 11, 2023

  4/26/2023

  Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”) today announced that it will issue its financial results for the fiscal 2023 second quarter ended March 31, 2023, on Thursday, May 11, 2023, after the close of the stock market.

• Inotiv, Inc. Announces First Quarter Fiscal 2023 Financial Results

  2/13/2023

  Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q1 FY 2023”) ended December 31, 2022.

• Inotiv, Inc. Announces Changes to Board of Directors - Jan 23, 2023

  1/23/2023

  Inotiv, Inc. announced that David Landman has been designated by Jermyn Street Associates LLC as its Shareholder Representative on the Board of Directors, replacing Scott Cragg, who is stepping down to focus on his position as Partner at AS Birch Grove.

• Inotiv, Inc. Announces Fourth Quarter and Full Year Fiscal 2022 Financial Results

  1/10/2023

  Inotiv, Inc. today announced financial results for the three months (“Q4 FY 2022”) and twelve months (“FY 2022”) ended September 30, 2022.

• Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings

  12/8/2022

  Inotiv, Inc. announced the opening of the second phase of its lab facility in Rockville, MD, the scheduled opening date of January 2023 for its pathology campus and training center in Kalamazoo, MI, and the opening and occupancy of the site expansion at its facility in Boulder, CO.

• Inotiv, Inc. to Participate in November Investor Conferences

  11/1/2022

  Inotiv, Inc. announced today that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, are scheduled to participate in the following investor conferences.

• Inotiv, Inc. Announces Third Quarter Fiscal 2022 Financial ResultsIncreases Select Fiscal Year 2022 Financial Guidance

  8/10/2022

  Inotiv, Inc., a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced financial results for the three months and nine months ended June 30, 2022.

• Inotiv, Inc. Expands Protein/Peptide Bioanalytical Capabilities with Acquisition of Protypia, Inc.

  7/7/2022

  Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company has completed the purchase of Nashville, Tennessee based Protypia, Inc. (“Protypia”)